The Impact of Radiotherapy on Oligometastatic Cancer

Launched by INSTITUT INVESTIGACIO SANITARIA PERE VIRGILI · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a specific type of radiation treatment, called Stereotactic Ablative Radiotherapy (SABR), can help patients with oligometastatic cancer. Oligometastatic cancer means that the cancer has spread to a limited number of places in the body, such as the bones, lungs, or liver. The goal of the trial is to gather information that can help doctors understand which patients might benefit the most from this treatment, ultimately aiming to improve survival rates.

To be eligible for the trial, participants need to be at least 18 years old and have a confirmed diagnosis of breast, prostate, lung, or colorectal cancer, with up to five metastases. They should also have a good performance status, meaning they are able to carry out daily activities without much difficulty. Participants can expect to receive personalized care and contribute to important research that could shape future cancer treatments. The trial is currently recruiting and welcomes individuals of all genders who meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologic confirmation of primary tumor: breast, prostate, lung, colorectal.
• • 18 years old or older.
• • Up to five metastases located in the bone, lung, node, liver or brain.
• • Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1.
• Exclusion Criteria:
• • Non-melanoma skin cancer.
• • Previous radiotherapy in the same anatomic location.
• • Presence of vascular collagen disease.
• • Pregnancy or lactation at the time of inclusion.